Previous 10 | Next 10 |
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility PR Newswire BETHESDA, Md. , Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ...
Check These 3 Penny Stocks Out For Your List in February After a wild day of trading penny stocks and blue chips, investors continue to search for the best stocks to buy. Now, while the trading day started off strong, it quickly devolved into another day of losses across the board. This...
Are These 3 Penny Stocks Worth Watching Right Now If you’re looking for the best penny stocks to buy, there are hundreds to choose from. As a result of the sheer number of penny stocks out there, finding the best ones for your watchlist is all about understanding where to loo...
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility PR Newswire BETHESDA, Md. , Dec. 21, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ...
NWBO still has not announced toppling data, or TLD. This situation has been ongoing for more than a year after data lock. I will continue to hold, but will not add to my small position. For further details see: Northwest Biotherapeutics: No TLD Yet
Northwest Biotherapeutics (OTCQB:NWBO +12.3%) has closed on $15M financing, which brings the company's cash reserves above $20M. The financing is in the form of a 22-month loan which requires no payments for 8 months, and then provides for a subsequent 14-month amortization period. Interest r...
Northwest Biotherapeutics Announces $15 Million Financing PR Newswire BETHESDA, Md. , Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® personalized immune therapies for solid tum...
Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility PR Newswire BETHESDA, Md. , Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ...
This is a recap of DCVax-L's pedigree. Stock is down 25% since my last neutral article. I am celebrating NWBO's one-year data lock anniversary with a buy. For further details see: Northwest Bio: Nowhere To Go But Up
NWBO's DCVax-L trial is being unblinded. The company is not presenting at ASCO. I expect this to close before year end. For further details see: Northwest Biotherapeutics: CEO Says Unblinding Is A Work In Progress
News, Short Squeeze, Breakout and More Instantly...
Northwest Biotherapeutics Inc. Company Name:
NWBO Stock Symbol:
OTCMKTS Market:
Northwest Biotherapeutics Inc. Website:
Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property PR Newswire Complementary to Technology & IP Already Owned or In-Licensed; Significant Step in Building a Leading Dendritic Cell Franchise ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors PR Newswire BETHESDA, Md. , March 21, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax ® ...